Semaglutide 0.25mg, 0.5mg, 1mg Injection — GLP-1 Receptor Agonist for Type 2 Diabetes
Ozempic® (Semaglutide) — Once-Weekly GLP-1 Receptor Agonist for Type 2 Diabetes
Gold Standard GLP-1 Therapy for Blood Sugar Control and Cardiovascular Risk Reduction
Ozempic® (Semaglutide) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood sugar control in adults with Type 2 diabetes. In addition to glycemic control, Ozempic has demonstrated significant cardiovascular benefits, reducing the risk of major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and established cardiovascular disease.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Ozempic (Semaglutide) to hospitals, diabetes clinics, nursing homes, and pharmacies across India. Manufactured by Novo Nordisk, a global leader in diabetes care, Ozempic is one of the most widely prescribed GLP-1 receptor agonists worldwide.
What is Ozempic (Semaglutide)?
Ozempic contains Semaglutide, a GLP-1 receptor agonist that mimics the natural GLP-1 hormone released by the intestine after meals. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite — resulting in improved blood sugar control and significant weight loss.
Semaglutide has 94% structural homology with native human GLP-1 but has been modified to resist degradation by the DPP-4 enzyme, giving it a half-life of approximately 1 week — enabling once-weekly dosing.
Full prescribing information is available at the FDA label for Semaglutide.
Clinical Studies and Evidence
SUSTAIN-6 Trial (Cardiovascular Outcomes) Published in the New England Journal of Medicine (2016), the SUSTAIN-6 trial demonstrated that Semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — by 26% compared to placebo in patients with Type 2 diabetes and high cardiovascular risk.
SUSTAIN-7 Trial (Semaglutide vs Dulaglutide) The SUSTAIN-7 trial showed that Semaglutide 1mg achieved superior HbA1c reduction and greater weight loss compared to Dulaglutide 1.5mg, confirming Ozempic’s position as a best-in-class GLP-1 receptor agonist.
SUSTAIN FORTE Trial (Semaglutide 2mg) The SUSTAIN FORTE trial showed that Semaglutide 2mg achieved greater HbA1c reduction compared to Semaglutide 1mg, leading to approval of the 2mg dose for patients requiring additional glycemic control.
STEP Programme (Weight Management) The STEP clinical trials programme evaluated Semaglutide for weight management and demonstrated average body weight reduction of 14.9% with Semaglutide 2.4mg (Wegovy) in patients with obesity, paving the way for Wegovy approval for weight management.
Available Strengths
Ozempic is available in the following strengths:
Each pre-filled pen contains multiple doses for once-weekly subcutaneous injection. Treatment starts at 0.25mg weekly for 4 weeks, then increases to the maintenance dose based on patient response and tolerability.
Indications — What Ozempic is Used For
Note: Ozempic is not indicated for Type 1 diabetes or as a substitute for insulin.
For detailed indication information refer to MedlinePlus Semaglutide.
Key Benefits of Ozempic
Proven HbA1c Reduction Ozempic consistently reduces HbA1c by 1.5% to 1.8% across clinical trials, helping patients achieve and maintain target blood sugar levels.
Significant Weight Loss Patients on Ozempic experience average weight loss of 4–6kg, making it particularly beneficial for overweight or obese patients with Type 2 diabetes.
Cardiovascular Protection Ozempic is one of the few diabetes medicines with proven cardiovascular benefit, reducing the risk of heart attack, stroke, and cardiovascular death in high-risk patients as demonstrated in the SUSTAIN-6 trial.
Once-Weekly Convenience Single weekly injection significantly improves patient compliance compared to daily injectable therapies, making long-term adherence easier for patients.
Low Risk of Hypoglycaemia Because Ozempic stimulates insulin secretion only when blood sugar is elevated (glucose-dependent mechanism), the risk of hypoglycaemia is low when used without insulin or sulfonylureas.
Renal Protective Effects Emerging evidence suggests Semaglutide may have nephroprotective effects, slowing the progression of diabetic kidney disease.
How Ozempic Works
Ozempic mimics the natural GLP-1 hormone to:
For a detailed explanation of Semaglutide’s mechanism, refer to the American Diabetes Association Standards of Care.
Ozempic vs Mounjaro — Key Differences
| Feature | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP (dual) |
| HbA1c Reduction | Up to 1.8% | Up to 2.4% |
| Average Weight Loss | 4–6kg | 12–22% body weight |
| Cardiovascular Evidence | Proven (SUSTAIN-6) | Ongoing (SURPASS-CVOT) |
| Dosing | Once weekly | Once weekly |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Available at A.K. Pharma | Request Quote | Request Quote |
Dosage and Administration
Full dosing guidelines available at Drugs.com Semaglutide Dosage.
Who Should Use Ozempic
Ozempic is prescribed for:
Ozempic is prescribed by endocrinologists, diabetologists, cardiologists, and general physicians. A.K. Pharma supplies Ozempic to hospitals, diabetes clinics, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain. These are most common when starting treatment and during dose escalation, and typically improve over time.
Serious side effects include:
Full side effect information available at FDA Semaglutide Safety Information.
Precautions
Storage and Handling
A.K. Pharma maintains all cold chain requirements during storage and supply of Ozempic, ensuring product integrity and efficacy for every unit supplied to hospitals and pharmacies across India.
Manufacturer Information
Ozempic (Semaglutide) is manufactured by Novo Nordisk A/S, a Danish pharmaceutical company and global leader in diabetes care with over 100 years of experience. Ozempic received FDA approval in December 2017 for Type 2 diabetes management and cardiovascular risk reduction. A.K. Pharma supplies only genuine Ozempic sourced from authorized distributors.
Related Diabetes and Obesity Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Ozempic used for? Ozempic (Semaglutide) is used to improve blood sugar control in adults with Type 2 diabetes and to reduce the risk of cardiovascular events in patients with Type 2 diabetes and established cardiovascular disease. More information available at MedlinePlus.
Q. What is the generic name of Ozempic? The generic name of Ozempic is Semaglutide. It belongs to the GLP-1 receptor agonist class of diabetes medicines.
Q. Is Ozempic available in India? Ozempic can be supplied to hospitals, clinics, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. How is Ozempic different from Mounjaro? Ozempic targets only GLP-1 receptors while Mounjaro targets both GLP-1 and GIP receptors. Mounjaro achieves greater HbA1c reduction and more significant weight loss. However Ozempic has stronger cardiovascular outcome data from the SUSTAIN-6 trial. Refer to the SURPASS-2 trial for a direct comparison.
Q. How is Ozempic different from Wegovy? Both Ozempic and Wegovy contain Semaglutide. Ozempic (0.5mg, 1mg, 2mg) is approved for Type 2 diabetes management. Wegovy (2.4mg) is approved specifically for chronic weight management in adults with obesity or overweight.
Q. What is the price of Ozempic in India? Ozempic price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Ozempic from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Ozempic in bulk? Yes. A.K. Pharma supplies Ozempic in bulk to hospitals, nursing homes, diabetes clinics, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Q. Where can I find clinical evidence for Ozempic? Key Ozempic clinical trials including SUSTAIN-6 are published in the New England Journal of Medicine. FDA approval information is available at FDA.gov.
Why Order Ozempic from A.K. Pharma?
Contact A.K. Pharma for Ozempic Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
